Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
To accelerate the development of next-generation radioconjugates to treat cancer
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Targeting deadly drug-resistant acinetobacter infections
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
